Abstract
During the last decades, the rapid development in molecular biology has contributed to the understanding of genetic factors underlying many adverse drug reactions. Until recently, most research in this area has focused on genes coding for drug-metabolizing enzymes. Inactivating mutations have been found in genes coding for enzymes belonging to the cytochrome P-450 system, which is the major system for drug metabolism in humans, but also in genes coding for other enzymes. Subjects with a lack of functional activity in these enzymes should be treated with very low doses of drugs metabolized by the same enzyme in order to avoid excessive drug levels and thereby toxic effects. In the last years, increasing attention has been directed towards genes coding for drug targets. Hitherto, most studies have been carried out on single genes known to be or assumed to be functionally related to a given adverse drug reaction. Another approach, which may become more common in the future, is testing for complex single nucleotide polymorphism patterns that may be associated with adverse drug reactions, although the functional relationship between them may be completely unknown. Due to the influence of non-genetic factors in the development of adverse drug reactions, the association between a specific genotype and an adverse drug reaction will always be lower than 100%. Therefore, there is a need for prospective large-scale studies in order to elucidate the extent of environmental influences on the adverse drug reactions for which a genetic basis has been suggested. Despite these obstacles, pharmacogenetic testing will hopefully in the future identify at least some clear-cut situations where a drug should be avoided in certain individuals in order to reduce the risk of adverse drug reactions.
Keywords: Genotyping, drug-metabolizing enzymes, pharmacogenetic
Current Topics in Medicinal Chemistry
Title: Genotyping as a Tool to Predict Adverse Drug Reactions
Volume: 4 Issue: 13
Author(s): Cuneyt Guzey and Olav Spigset
Affiliation:
Keywords: Genotyping, drug-metabolizing enzymes, pharmacogenetic
Abstract: During the last decades, the rapid development in molecular biology has contributed to the understanding of genetic factors underlying many adverse drug reactions. Until recently, most research in this area has focused on genes coding for drug-metabolizing enzymes. Inactivating mutations have been found in genes coding for enzymes belonging to the cytochrome P-450 system, which is the major system for drug metabolism in humans, but also in genes coding for other enzymes. Subjects with a lack of functional activity in these enzymes should be treated with very low doses of drugs metabolized by the same enzyme in order to avoid excessive drug levels and thereby toxic effects. In the last years, increasing attention has been directed towards genes coding for drug targets. Hitherto, most studies have been carried out on single genes known to be or assumed to be functionally related to a given adverse drug reaction. Another approach, which may become more common in the future, is testing for complex single nucleotide polymorphism patterns that may be associated with adverse drug reactions, although the functional relationship between them may be completely unknown. Due to the influence of non-genetic factors in the development of adverse drug reactions, the association between a specific genotype and an adverse drug reaction will always be lower than 100%. Therefore, there is a need for prospective large-scale studies in order to elucidate the extent of environmental influences on the adverse drug reactions for which a genetic basis has been suggested. Despite these obstacles, pharmacogenetic testing will hopefully in the future identify at least some clear-cut situations where a drug should be avoided in certain individuals in order to reduce the risk of adverse drug reactions.
Export Options
About this article
Cite this article as:
Guzey Cuneyt and Spigset Olav, Genotyping as a Tool to Predict Adverse Drug Reactions, Current Topics in Medicinal Chemistry 2004; 4 (13) . https://dx.doi.org/10.2174/1568026043387791
DOI https://dx.doi.org/10.2174/1568026043387791 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Impact of Alzheimers Disease on the Functional Connectivity of Spontaneous Brain Activity
Current Alzheimer Research Revisiting the Medical Management of Parkinson’s Disease: Levodopa versus Dopamine Agonist
Current Neuropharmacology Voltammetric Sensing of Bilirubin Based on Nafion/Electrochemically Reduced Graphene Oxide Composite Modified Glassy Carbon Electrode
Current Analytical Chemistry Disease-Related Changes in TRPV1 Expression and Its Implications for Drug Development
Current Topics in Medicinal Chemistry AICD Nuclear Signaling and Its Possible Contribution to Alzheimers Disease
Current Alzheimer Research Comparative Proteomics and Bioinformatics Analysis of Tissue from Non-Small Cell Lung Cancer Patients
Current Proteomics Cysteine Network (CYSTEINET) Dysregulation in Parkinson’s Disease: Role of N-acetylcysteine
Current Drug Metabolism Psychiatric/Psychosocial Rehabilitation (PSR) in Relation to Vocational and Educational Environments: Work and Learning
Current Psychiatry Reviews Melatonin Metabolism in the Central Nervous System
Current Neuropharmacology Application of Vibrational Spectroscopy to Study Solid-state Transformations of Pharmaceuticals
Current Pharmaceutical Design Editorial: Asleep at the Wheel: Concerning Driving after Co-Consumption of Alcohol and Benzodiazepines
Current Drug Abuse Reviews Pharmacotherapy & Surgical Interventions Available for Obesity Management and Importance of Pancreatic Lipase Inhibitory Phytomolecules as Safer Anti-Obesity Therapeutics
Mini-Reviews in Medicinal Chemistry Recent Advances in Progressive Supranuclear Palsy: A Review
Current Alzheimer Research Phosphodiesterase: An Interface Connecting Cognitive Deficits to Neuropsychiatric and Neurodegenerative Diseases
Current Pharmaceutical Design An Updated Patent Review on Ocular Drug Delivery Systems with Potential for Commercial Viability
Recent Patents on Drug Delivery & Formulation Metabotropic Glutamate Receptor 7 (mGluR7) as a Target for Modulating Pain-evoked Activities of Neurons in the Hippocampal CA3 Region of Rats
CNS & Neurological Disorders - Drug Targets Metal Protein Attenuating Compounds (MPACs): An Emerging Approach for the Treatment of Neurodegenerative Disorders
Current Bioactive Compounds Hypertension in Pregnancy: Pathophysiology & Management Strategies
Current Pharmaceutical Design Cultivating a Trauma Awareness Culture in the Addictions
Current Drug Abuse Reviews "Neuro-Semeiotics" and "Free-Energy Minimization" Suggest a Unified Perspective for Integrative Brain Actions: Focus on Receptor Heteromers and Roamer Type of Volume Transmission
Current Protein & Peptide Science